These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18027850)

  • 1. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
    Qian X; Ara G; Mills E; LaRochelle WJ; Lichenstein HS; Jeffers M
    Int J Cancer; 2008 Mar; 122(6):1400-10. PubMed ID: 18027850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
    Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.
    Monks A; Hose CD; Pezzoli P; Kondapaka S; Vansant G; Petersen KD; Sehested M; Monforte J; Shoemaker RH
    Anticancer Drugs; 2009 Sep; 20(8):682-92. PubMed ID: 19606018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo.
    Buckley MT; Yoon J; Yee H; Chiriboga L; Liebes L; Ara G; Qian X; Bajorin DF; Sun TT; Wu XR; Osman I
    J Transl Med; 2007 Oct; 5():49. PubMed ID: 17935615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
    Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
    Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
    Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
    Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
    Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
    Butler LM; Webb Y; Agus DB; Higgins B; Tolentino TR; Kutko MC; LaQuaglia MP; Drobnjak M; Cordon-Cardo C; Scher HI; Breslow R; Richon VM; Rifkind RA; Marks PA
    Clin Cancer Res; 2001 Apr; 7(4):962-70. PubMed ID: 11309347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of radiation response by histone deacetylase inhibition.
    Chinnaiyan P; Vallabhaneni G; Armstrong E; Huang SM; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):223-9. PubMed ID: 15850925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
    Chien W; Lee DH; Zheng Y; Wuensche P; Alvarez R; Wen DL; Aribi AM; Thean SM; Doan NB; Said JW; Koeffler HP
    Mol Carcinog; 2014 Sep; 53(9):722-35. PubMed ID: 23475695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HDAC6-dependent carcinogenesis: emerging, new therapeutic options besides belinostat.
    Kapoor S
    Int J Cancer; 2009 Jan; 124(2):509. PubMed ID: 18942705
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
    Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
    Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.
    Kim MJ; Lee JS; Park SE; Yi HJ; Jeong IG; Kang JS; Yun J; Lee JY; Ro S; Lee JS; Choi EK; Hwang JJ; Kim CS
    J Urol; 2015 May; 193(5):1660-8. PubMed ID: 25433307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.
    Havas AP; Rodrigues KB; Bhakta A; Demirjian JA; Hahn S; Tran J; Scavello M; Tula-Sanchez AA; Zeng Y; Schmelz M; Smith CL
    Cancer Biol Ther; 2016 Dec; 17(12):1240-1252. PubMed ID: 27791595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor.
    Gimsing P
    Expert Opin Investig Drugs; 2009 Apr; 18(4):501-8. PubMed ID: 19335278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer clinical efficiency and stochastic mechanisms of belinostat.
    El Omari N; Bakrim S; Khalid A; Albratty M; Abdalla AN; Lee LH; Goh KW; Ming LC; Bouyahya A
    Biomed Pharmacother; 2023 Sep; 165():115212. PubMed ID: 37541175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
    Tumber A; Collins LS; Petersen KD; Thougaard A; Christiansen SJ; Dejligbjerg M; Jensen PB; Sehested M; Ritchie JW
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):275-83. PubMed ID: 17124594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring the effect of belinostat in solid tumors by H4 acetylation.
    Marquard L; Petersen KD; Persson M; Hoff KD; Jensen PB; Sehested M
    APMIS; 2008 May; 116(5):382-92. PubMed ID: 18452428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.